CD95 and CD95L promote and protect cancer stem cells

被引:0
|
作者
Paolo Ceppi
Abbas Hadji
Frederick J. Kohlhapp
Abhinandan Pattanayak
Annika Hau
Xia Liu
Huiping Liu
Andrea E. Murmann
Marcus E. Peter
机构
[1] Feinberg School of Medicine,Division Hematology/Oncology
[2] Northwestern University,Department of Pathology and Case Comprehensive Cancer Center
[3] School of Medicine,undefined
[4] Case Western Reserve University,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
CD95 (APO-1/Fas) is a death receptor used by immune cells to kill cancer cells through induction of apoptosis. However, the elimination of CD95 or its ligand, CD95L, from cancer cells results in death induced by CD95R/L elimination (DICE), a type of cell death that resembles a necrotic form of mitotic catastrophe suggesting that CD95 protects cancer cells from cell death. We now report that stimulation of CD95 on cancer cells or reducing miR-200c levels increases the number of cancer stem cells (CSCs), which are more sensitive to induction of DICE than non-CSC, while becoming less sensitive to CD95-mediated apoptosis. In contrast, induction of DICE or overexpression of miR-200c reduces the number of CSCs. We demonstrate that CSCs and non-CSCs have differential sensitivities to CD95-mediated apoptosis and DICE, and that killing of cancer cells can be maximized by concomitant induction of both cell death mechanisms.
引用
收藏
相关论文
共 50 条
  • [1] CD95 and CD95L promote and protect cancer stem cells
    Ceppi, Paolo
    Hadji, Abbas
    Kohlhapp, Frederick J.
    Pattanayak, Abhinandan
    Hau, Annika
    Liu, Xia
    Liu, Huiping
    Murmann, Andrea E.
    Peter, Marcus E.
    NATURE COMMUNICATIONS, 2014, 5
  • [2] CD95/CD95L interactions and their role in autoimmunity
    Ricci-Vitiani, L
    Conticello, C
    Zeuner, A
    De Maria, R
    APOPTOSIS, 2000, 5 (05) : 419 - 424
  • [3] CD95/CD95L interactions and their role in autoimmunity
    L. Ricci-Vitiani
    C. Conticello
    A. Zeuner
    R. De Maria
    Apoptosis, 2000, 5 : 419 - 424
  • [4] CD95 and CD95L in gastrointestinal cancer patients peripheral blood
    Jaunalksne, Into
    Donina, Simona
    Engele, Ludmila
    Romanova, Tatjana
    CLINICAL IMMUNOLOGY, 2008, 127 : S146 - S146
  • [5] CD95 ligand (CD95L) in normal human lymphoid tissues -: A subset of plasma cells are prominent producers of CD95L
    Sträter, J
    Mariani, SM
    Walczak, H
    Rücker, FG
    Leithäuser, F
    Krammer, PH
    Möller, P
    AMERICAN JOURNAL OF PATHOLOGY, 1999, 154 (01): : 193 - 201
  • [6] The CD95/CD95L signaling pathway: A role in carcinogenesis
    Fouque, Arnelie
    Debure, Laure
    Legembre, Patrick
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2014, 1846 (01): : 130 - 141
  • [7] The CD95(APO-1/Fas)/CD95L system
    Krammer, PH
    TOXICOLOGY LETTERS, 1998, 103 : 131 - 137
  • [8] Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases
    Risso, Vesna
    Lafont, Elodie
    Le Gallo, Matthieu
    CELL DEATH & DISEASE, 2022, 13 (03)
  • [9] The dual role of the CD95 and CD95L signaling pathway in glioblastoma
    Zhang, Yanrui
    Jin, Taian
    Dou, Zhangqi
    Wei, Boxing
    Zhang, Buyi
    Sun, Chongran
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [10] Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases
    Vesna Risso
    Elodie Lafont
    Matthieu Le Gallo
    Cell Death & Disease, 13